Who are AB-106, Rifampicin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Standard dose rifampicin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ab-106-rifampicin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

AB-106, Rifampicin — Competitive Intelligence Brief

AB-106, Rifampicin (AB-106, Rifampicin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bactericidal antibiotic. Area: Infectious Disease.

phase 1 Bactericidal antibiotic Beta subunit of bacterial RNA polymerase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

AB-106, Rifampicin (AB-106, Rifampicin) — Nuvation Bio Inc.. Inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AB-106, Rifampicin TARGET	AB-106, Rifampicin	Nuvation Bio Inc.	phase 1	Bactericidal antibiotic	Beta subunit of bacterial RNA polymerase
Standard dose rifampicin	Standard dose rifampicin	Radboud University Medical Center	phase 3	Bacterial RNA polymerase inhibitor	beta subunit of bacterial RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bactericidal antibiotic class)

Nuvation Bio Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AB-106, Rifampicin — Competitive Intelligence Brief. https://druglandscape.com/ci/ab-106-rifampicin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab